Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen for Myotonic Dystrophy Type 1
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen for Myotonic Dystrophy Type 1
Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
Nine Mile Metals Announces Certified Assays from DDH-WD-25-01 of 3.83% CuEq Over 22.65 Meters (39.52 g/t Ag, 0.96 g/t Au, 0.99% Cu, 2.25% Pb, 1.61% Zn) and 4.33% CuEq Over 17.65 Meters (42.5 g/t Ag, 1.01 g/t Au, 1.2% Cu, 2.62% Pb, 2.05% Zn) Including 1.21 g/t Au and 50.33 g/t Ag Over 13.00 Meters
